跳至主要内容
临床试验/NCT06914544
NCT06914544招募中不适用

Hypofractionated Radiosurgery for Localised Prostate Cancer (HYPOSTAT-III)

University Hospital Schleswig-Holstein11 个研究点 分布在 1 个国家目标入组 175 人开始时间: 2025年12月10日最近更新:
适应症
干预措施

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
175
试验地点
11
主要终点
GU and GI Toxicity

研究概览

简要总结

Hypofractionated radiosurgery with 5 fractions is considered standard of care for localized prostate cancer. The investigators initiated this multicenter phase II prospective trial to analyse feasibility (toxicity) of hypofractionated radiosurgery with 3 fractions in patients with localised prostate cancer under the hypothesis that the ratio of patients with late GU and GI toxicity ≥ grade 2 after 1 year amounts to 8.4% and 1.3% and is significant lower than 16.4% and 5.7% currently.

详细描述

Experimental radiosurgery of the prostate with 3 fractions each with 9.5 -10.5 Gy (total application rate of 28.5-31.5 Gy) based on risk grading.

Planned visits are: Baseline, visits at every radiation day and four follow ups (4-6 weeks, 3 months, 6 months and one year after last day of radiation).

研究设计

研究类型
Interventional
分配方式
Na
干预模型
Single Group
主要目的
Treatment
盲法
None

入排标准

年龄范围
18 Years 至 —(Adult, Older Adult)
性别
Male
接受健康志愿者

入选标准

  • Localised, histopathologically confirmed Prostate Cancer (cT1-T2c N0 M0)
  • Gleason-grade ≤7, ISUP Grade Group 1-3
  • Guideline-based staging
  • Age ≥ 18 years
  • PSA < 20 ng/ml
  • Volume of the prostate < 80 cm³
  • IPSS-Score ≤ 12
  • Written informed consent

排除标准

  • History of prior pelvic radiotherapy
  • Previous transurethral resection, laser enucleation or prostate ablation
  • Contraindication to MRI or Fiducial marker implantation (e.g. gold allergy)
  • Relevant comorbidity thought to adversely affect treatment compliance
  • Legal incapacity or lack of informed consent

研究组 & 干预措施

Hypofractionated Radiosurgery

Experimental

3 fractions with 9.5-10.5 Gy, total dose 28.5-31.5 Gy

干预措施: Hypofractionated Radiosurgery (Radiation)

结局指标

主要结局

GU and GI Toxicity

时间窗: 12-15 months after radiotherapy

Late toxicity measured with Radiation Therapy Oncology Group-(RTOG)-Score

次要结局

  • Acute toxicity(Through study completion)
  • PSA(At the time of inclusion and 1, 3, 6-9 and 12-15 months after radiotherapy)
  • IPSS(Screening and 3, 6-9 and 12-15 months after radiotherapy)
  • Quality of Life Score(At the time of inclusion and 12-15 months after radiotherapy)
  • Decision Regret Score(At the time of inclusion and 12-15 months after radiotherapy)

研究者

发起方
University Hospital Schleswig-Holstein
申办方类型
Other
责任方
Sponsor

研究点 (11)

Loading locations...

相似试验